CHAPEL HILL — UNC Lineberger Comprehensive Cancer Center has appointed two new associate directors to lead and develop strategic priorities as the center expands clinical programs in the new N.C. Cancer Hospital and research initiatives among its 300 faculty members.
Lisa Carey, MD, has been named associate director for clinical science, and Ned Sharpless, MD, has been named associate director for translational research for the UNC Lineberger Comprehensive Cancer Center.
Carey is associate professor of medicine, medical director of the UNC Breast Center, and co-leader of UNC Lineberger’s breast cancer program. She has emerged as a national leader in breast cancer clinical trials and the application of genetics and genomics to patient care. Sharpless is associate professor of medicine, and co-leader of UNC Lineberger’s molecular therapeutics program. His groundbreaking work on tumor suppressor genes is leading to new strategies to both understand and treat cancer in novel ways.
“UNC Lineberger is growing, especially with the opening of the N.C. Cancer Hospital and an increasing number of patients and collaborations with hospitals and practices across North Carolina,” said Shelton Earp, MD, center director.
“Our job as a public comprehensive cancer center is to devise better methods of cancer prevention, early detection and therapy. Lisa and Ned will provide intellectual leadership in key areas translating laboratory science into clinical practice. All cancer centers face this challenge and by appointing these two nationally recognized faculty members, UNC Lineberger can accelerate and develop these initiatives in a strategic way.”
In her new position, Carey is responsible for promoting clinical sciences across all cancer programs with particular emphasis on developing clinical trials. She oversees research facilities that emphasize correlative science, the measurement of biological responses in the conduct of prevention and treatment trials.
In his new position, Sharpless is responsible for promoting and integrating pre-clinical translational activities: drug discovery, cancer models development, and, as the science moves forward, intellectual properties and commercialization. He oversees research facilities used by faculty converting basic laboratory findings into clinical application.
Carey earned her medical degree from Johns Hopkins, was a resident there in Internal Medicine then a fellow in Oncology from 1990 to 1997. She earned an advanced degree in clinical research at the Johns Hopkins School of Public Health from 1994-98, and joined the UNC faculty in 1998. She is a member of the National Cancer Institute Breast Cancer Steering Committee, a group that functions to coordinate an efficient, cost-effective, science-driven, and transparent process to identify and promote the "best science" in breast cancer clinical research by addressing the design and prioritization of phase III trials in breast cancer and large phase II studies.
Sharpless, a UNC-Chapel Hill Morehead Scholar, earned his medical degree from the UNC School of Medicine. He completed a residency in internal medicine at Massachusetts General Hospital and then a fellowship in hematology and oncology at Harvard Medical School and Dana-Farber Cancer Institute. Prior to joining the UNC faculty in 2002, he was an instructor in medicine at Harvard.
UNC Lineberger contact:
Dianne Shaw, (919) 966-7834